Breaking News Instant updates and real-time market news.

MNK

Mallinckrodt

$27.13

0.94 (3.59%)

16:04
10/12/18
10/12
16:04
10/12/18
16:04

D.E. Shaw reports 5.1% passive stake in Mallinckrodt

  • 23

    Oct

  • 06

    Nov

MNK Mallinckrodt
$27.13

0.94 (3.59%)

10/03/18
BMOC
10/03/18
NO CHANGE
Target $37
BMOC
Outperform
Approval of Noxivent has mitigating factors for Mallinckrodt, says BMO Capital
BMO Capital analyst Gary Nachman kept his Outperform rating and $37 price target on Mallinckrodt (MNK), saying the FDA's approval of Praxair (PX) ANDA for Noxivent, which is a generic form of gas used in the Inomax device for "treating neonates with respiratory failure", has some mitigating factors. The analyst notes that Praxair's device will still have to be approved by the FDA and litigation appeal between the two companies regarding Inomax patents is still ongoing until the first half of next year, with the possibility of a favorable settlement between the two still possible. Moreover, Nachman points to Mallinckrodt's "very strong relationships" with partner hospitals' NICUs, as 25% of its U.S. book of business has been committed for the next couple of years.
10/04/18
STFL
10/04/18
NO CHANGE
Target $30
STFL
Hold
Mallinckrodt selloff today on Praxair ANDA an overreaction, says Stifel
Mallinckrodt (MNK) shares are down sharply this morning following abbreviated new drug application approval of Praxair's (PX) Noxivent, Stifel analyst Annabel Samimy tells investors in a research note. Noxivent's filing as a generic has given investors pause that the gas will be used as a substitute to Mallinckrodt's nitrous oxide in the INOmax System - the leading nitric oxide vasodilator for respiratory failure in term/near-term infants, the analyst says. However, Samimy points out that Noxivent cannot be interchanged with the nitric oxide gas used in the INOmax System, and that thus far, we have not seen a 510(k) approval from the FDA for Praxair's device. Further, the analyst adds that the pending Praxair system will be another branded competitor and not a generic substitute, which she think's today's selloff implies. The analyst also believes consensus estimates have reflected potential competition for well over a year. As such, Samimy thinks today's selloff in Mallinckrodt is overreaction to a "known event". She believes Mallinckrodt is "well-positioned to defend its share." The analyst, nonetheless, keeps a Hold rating on the stock with a $30 price target. The shares in afternoon trading are down 17%, or $5.18, to $25.95.
10/05/18
JEFF
10/05/18
NO CHANGE
Target $35
JEFF
Buy
Mallinckrodt 17% selloff yesterday 'well overdone,' says Jefferies
Jefferies analyst Anthony Petrone views the 17% selloff yesterday in shares of Mallinckrodt (MNK) as "well overdone." The pullback on Praxair's (PX) abbreviated new drug application clearance of Noxivent effectively prices in a $130M revenue shortfall on Mallinckrodt's INOmax in the near term, Petrone tells investors in a research note. Conversely, the analyst expects a more gradual erosion given the ongoing patent appeal process, potential label extension on INOmax, and the need for infrastructure investment on the part of Praxair. He keeps a Buy rating on Mallinckrodt with a $35 price target.
10/08/18
10/08/18
NO CHANGE
Target $24

Market Perform
Wells cuts Mallinckrodt target to $24 after confirming Praxair generic approval
Wells Fargo analyst David Maris says he confirmed this morning with Praxair (PX) that the device associated with generic Inomax has been approved. Praxair would not provide any additional details around the launch timing or pricing plans, Maris tells investors in a research note. The analyst lowered his price target for Mallinckrodt (MNK) shares to $24 from $30 after reducing his estimates to account for the generic taking approximately 20% share over the next several years. He models Mallinckrodt's Inomax going from a 5% grower to a slight decline. Maris admits, however, that there are "strong reasons" to think Inomax has a more defensible position than losing 20% share, such as a loyal installed base and a high service level. Nonetheless, he believes uncertainty around the generic device approval warrant a reduced outlook. The analyst keeps a Market Perform rating on Mallinckrodt. The stock in morning trading is down 5c to $25.83.

TODAY'S FREE FLY STORIES

KOF

Coca-Cola Femsa

$59.41

-1.75 (-2.86%)

09:36
10/23/18
10/23
09:36
10/23/18
09:36
Upgrade
Coca-Cola Femsa rating change  »

Coca-Cola Femsa upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORCL

Oracle

$47.93

0.34 (0.71%)

09:35
10/23/18
10/23
09:35
10/23/18
09:35
Initiation
Oracle initiated  »

Oracle initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 14

    Nov

09:35
10/23/18
10/23
09:35
10/23/18
09:35
Conference/Events
JPMorgan European & EMEA analysts to hold analyst/industry conference call »

European Utilities…

ABBV

AbbVie

09:35
10/23/18
10/23
09:35
10/23/18
09:35
Initiation
AbbVie initiated  »

AbbVie initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

SNY

Sanofi

09:35
10/23/18
10/23
09:35
10/23/18
09:35
Initiation
Sanofi initiated  »

Sanofi reinitiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 28

    Oct

  • 29

    Oct

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

RHHBY

Roche

09:35
10/23/18
10/23
09:35
10/23/18
09:35
Initiation
Roche initiated  »

Roche reinitiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 24

    Dec

09:35
10/23/18
10/23
09:35
10/23/18
09:35
General news
Treasury 2-year auction outlook: the $38 B 2-year sale »

Treasury 2-year auction…

PFE

Pfizer

$44.37

-0.13 (-0.29%)

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
Pfizer initiated  »

Pfizer reinitiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 07

    Nov

GSK

GlaxoSmithKline

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
GlaxoSmithKline initiated  »

GlaxoSmithKline…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 31

    Oct

  • 07

    Nov

LLY

Eli Lilly

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
Eli Lilly initiated  »

Eli Lilly reinitiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 07

    Nov

NVS

Novartis

$87.12

-0.07 (-0.08%)

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
Novartis initiated  »

Novartis reinitiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

MRK

Merck

$72.56

0.22 (0.30%)

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
Merck initiated  »

Merck reinitiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

BMY

Bristol-Myers

$50.87

-3.44 (-6.33%)

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
Bristol-Myers initiated  »

Bristol-Myers reinitiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

  • 20

    May

AZN

AstraZeneca

$39.50

0.295 (0.75%)

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Initiation
AstraZeneca initiated  »

AstraZeneca reinitiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 07

    Nov

MLCO

Melco Resorts & Entertainment

$17.74

-0.04 (-0.22%)

09:34
10/23/18
10/23
09:34
10/23/18
09:34
Downgrade
Melco Resorts & Entertainment rating change  »

Melco Resorts &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLF

Financial Select Sector

$26.10

-0.56 (-2.10%)

, BAC

Bank of America

$27.36

-0.95 (-3.36%)

09:33
10/23/18
10/23
09:33
10/23/18
09:33
Technical Analysis
Technical Take: Bank of America drops in early trading »

The shares were last down…

XLF

Financial Select Sector

$26.10

-0.56 (-2.10%)

BAC

Bank of America

$27.36

-0.95 (-3.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

UTX

United Technologies

$126.42

-2.22 (-1.73%)

09:33
10/23/18
10/23
09:33
10/23/18
09:33
Hot Stocks
United Technologies says geo-political outlook is the biggest concern »

Says tariffs present a 5c…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

UBS

UBS

$13.77

-0.085 (-0.61%)

09:32
10/23/18
10/23
09:32
10/23/18
09:32
Periodicals
UBS backs down warning to staff about traveling to China, FT reports »

UBS has rescinded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXPI

eXp World Holdings

$12.50

0.35 (2.88%)

09:31
10/23/18
10/23
09:31
10/23/18
09:31
Hot Stocks
eXp Realty to acquire ShowMeNow, terms not disclosed »

eXp Realty, a subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

HOG

Harley-Davidson

$38.72

-0.84 (-2.12%)

09:31
10/23/18
10/23
09:31
10/23/18
09:31
Hot Stocks
Harley-Davidson says FY18 shipments will finish at low-end of guidance range »

Management says adapting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ORCL

Oracle

$47.93

0.34 (0.71%)

, AMZN

Amazon.com

$1,789.00

25.09 (1.42%)

09:30
10/23/18
10/23
09:30
10/23/18
09:30
Periodicals
Move from Oracle cause of Amazon warehouse outage on Prime Day, CNBC says »

Amazon (AMZN) dealt with…

ORCL

Oracle

$47.93

0.34 (0.71%)

AMZN

Amazon.com

$1,789.00

25.09 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 14

    Nov

HAL

Halliburton

$36.36

-1.18 (-3.14%)

09:30
10/23/18
10/23
09:30
10/23/18
09:30
Recommendations
Halliburton analyst commentary  »

Halliburton price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBAN

Huntington Bancshares

$13.66

-0.54 (-3.80%)

09:27
10/23/18
10/23
09:27
10/23/18
09:27
Hot Stocks
Huntington Bancshares to make targeted investments in people, technology »

Says local economies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

YMAB

Y-mAbs Therapeutics

$22.00

0.02 (0.09%)

09:27
10/23/18
10/23
09:27
10/23/18
09:27
Hot Stocks
Y-mAbs Therapeutics receives recommendation from COMP for OMPD for naxitamab »

Y-mAbs Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$6.84

0.02 (0.29%)

09:26
10/23/18
10/23
09:26
10/23/18
09:26
Upgrade
Snap rating change  »

Snap upgraded to Positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 07

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.